Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 1

Conditions

Nasopharyngeal Carcinoma 12Esophageal Squamous Cell Carcinoma 4Carcinoma, Transitional Cell 3Squamous Cell Carcinoma of Head and Neck 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Triple Negative Breast Neoplasms 1Treatment-naive Advanced Non-small Cell Lung Cancer 1Small Cell Lung Carcinoma 1Resectable Stage II-III Non-Small Cell Lung Cancer (NSCLC) 1Recurrence 1Radiotherapy 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Locally Advanced or Metastatic GC and GCJ Adenocarcinoma 1Hodgkin Disease 1Esophageal Neoplasms 1Colorectal Neoplasms, Hereditary Nonpolyposis 1Cholangiocarcinoma 1Cervical Cancer Metastatic 1Carcinoma, Renal Cell 1Breast Neoplasms 1Advanced or Metastatic Esophageal Squamous Cell Cancer Without Previous Systemic Chemotherapy 1

Interventions

toripalimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Cervical Cancer Metastatic × toripalimab × Clear all
NCT07392060 2026-02-06

A Phase III Clinical Study of WX390 Combined With Toripalimab Versus Investigator's Choice of Therapy in Patients With Recurrent or Metastatic Cervical Cancer Who Have Failed Prior Platinum-Based Treatment

Shanghai Jiatan Pharmatech Co., Ltd

Phase 3 Not yet recruiting
440 enrolled
Gynecologic

Cervical Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡